Related Experiment Video
Updated: Mar 1, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.9K
Linagliptin-associated blistering and ulceration.
Cristina Psomadakis1, Naima Shahzad2, Jonathan Katz2
1Acute Medicine Department, Whittington Hospital, London, UK.
BMJ Case Reports
|June 2, 2017
Summary
A patient with type 2 diabetes experienced rare blistering skin reactions from linagliptin, a common DPP-4 inhibitor. This highlights the importance of recognizing uncommon side effects of diabetes medications.
Area of Science:
- Endocrinology
- Dermatology
- Pharmacology
Background:
- Dipeptidyl peptidase 4 (DPP-4) inhibitors are widely used oral hypoglycemic agents for type 2 diabetes management.
- Adverse skin reactions are a known, though less common, side effect associated with some DPP-4 inhibitors.
Observation:
- A 60-year-old male with type 2 diabetes developed blistering on his hands after initial exposure to linagliptin.
- Upon re-exposure, the patient developed severe blistering on his foot, leading to secondary infection and hospitalization.
Findings:
- This case demonstrates a clear link between linagliptin exposure and the development of bullous dermatoses.
- The adverse skin reactions resolved after drug discontinuation, supporting a causal relationship.
Implications:
- Clinicians should be aware of the potential for rare but severe skin reactions with DPP-4 inhibitors like linagliptin.
- Prompt recognition and management of these reactions are crucial to prevent complications such as infection and prolonged morbidity in diabetic patients.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
787
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
787
01:06Oral Hypoglycemic Agents: Glinides
760
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
760
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
741
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
741
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
687
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
687
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K